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1.  ABSTRACT 
 
Decreased consumption of n-3 fatty acids (FA) 
and diets rich in animal proteins, saturated fats and n-6 
vegetable oils are associated with a higher incidence of 
cardiovascular disease (CVD), certain malignancies and 
autoimmune disorders such as rheumatoid arthritis and 
Systemic Lupus Erythromatous (SLE), and renal disease. 
Recent studies show that reduced calorie intake and 
supplementation of diet with n-3 FA delays the onset of 
autoimmune renal disease, primarily, due to increased 
antioxidant enzyme activities, decreased NF-kappaB 
activation and decreased IL-1, IL-6 and TNF-alpha mRNA 
expression in the kidney tissue. Studies in rodents show 
that addition of n-3 FA and soy protein to diet affords 
protection against bone loss induced by ovariectomy in 
mice due to NF-kappaB expression and decreased 
activation of osteoclasts. Together, the availale evidence 
show that increased daily intake of dietary n-3 FA 
decreases the severity of autoimmune disorders, lessens the 




























2.1. Role of n-3 fatty acids in health and disease 
  Since the original report of Bang et al. (1) on the 
diet consumed by Greenland Eskimos and the decreased 
incidence of cardiovascular disease (CVD), there has been 
considerable interest in the use of n-3 fatty acids (FA) as 
dietary supplements, and in the clinical setting (2,3).  
Several studies have shown promising results against 
inflammatory disorders including cardiovascular and 
autoimmune disorders (4,5).  It is now accepted that the use 
of n-3 FA may decrease the risk of CVD in the US 
population (6).  n-3 FA also decreased the incidence of 
several chronic diseases that are closely linked to increased 
consumption of saturated fat and n-6 vegetable oil in the 
USA (7).  A recent health study in nurses revealed that 
higher consumption of fish and n-3 fatty acids as well as 
fruits and vegetables was associated with a lower risk of 
heart disease (HD), particularly HD related deaths (8).  
Furthermore, the blood level of n-3 FA is a predictive 
biomarker for sudden death in men (4,9). Although the 
mechanism of n-3 FA mediated inhibition of inflammation 
n-3 fatty acids on autoimmunity and osteoporosis 
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and CVD is not fully understood, a great deal of supportive 
evidence indicates that alterations in arachidonic acid-
eicosanoid pathway intermediates, changes in lipid 
metabolism and/or decreases in pro-inflammatory cytokine 
production, along with changes in expression of  numerous 
genes and transcription factors are clearly involved (10-16).  
   
       The majority of studies on the effects of n-3 FA 
have been carried out using fish oil (FO) or FO 
concentrates containing low levels of EPA and DHA.  
Since there is significant interconversion of EPA and DHA 
in vivo, it is difficult to infer the effects of either of them 
with absolute certainty even if purified forms EPA or DHA 
are used.  However, effects on brain growth and 
development and visual acuity in infants are ascribed to 
DHA, since DHA is preferentially taken up in the brain and 
found in high concentrations in brain tissue.  DHA is 
reported to promote neurite growth and strengthen 
periventricular vascular system against hemorrhage (17).   
 
It is widely accepted that FO, rich in n-3 
polyunsaturated FA, protect against several types of 
cardiovascular diseases such as myocardial infarction, 
arrhythmia, atherosclerosis, and hypertension (18,19). 
Although, the precise cellular and molecular mechanisms 
for these beneficial effects are still unknown, one of the 
mechanisms may be their direct effects on vascular smooth 
muscle cell functions. These n-3 PUFAs activate K+ ATP 
channels and inhibit certain types of Ca2+ channels (20). 
There are at least two mechanisms for these actions: 1) 
n-3 PUFAs can alter the eicosanoid profile and 
cytokine-induced expression of inducible nitric oxide 
synthase and COX-2 through modulation of signaling 
transduction pathways, and 2) n-3 PUFAs can modulate 
vascular smooth muscle cell proliferation, migration, 
and apoptosis.  Recent studies strongly suggest that 
DHA has more potent and beneficial effects than EPA in 
these systems (21). DHA has been reported to be more 
potent at decreasing plasma triglyceride levels, as well 
as DHA supplementation alone significantly increases 
serum HDL cholesterol levels (22,23), which is 
associated with reduced risk of coronary heart disease 
(24) by being a more efficient reverse cholesterol 
transport pathway.  At least a portion of the 
hypotriglyceridemic effect of n-3 FA has been attributed 
to increasing circulating apoE levels (25). 
 
 Besides, numerous beneficial effects of n-3 FA 
on several other chronic diseases including osteoporosis 
are reported. Some clinical FO studies did not show 
anticipated benefits, maybe because of the variability in 
the quantity and quality of FO used, the oils used as 
controls, patient selection, absence of antioxidants to 
prevent rancidity of oils, and lack of availability of 
concentrated FO. At present, odor-free oils highly 
enriched in EPA and DHA are available and only a few 
capsules per day are needed to produce favorable results 
(26). A recent study has shown that dietary 
supplementation with FO may be beneficial in 
modifying symptomatic disease activity in SLE patients 
(27).  
 
2.2. n-3 fatty acids on autoimmunity 
 Since n-3 FA have been found to increase 
apoptosis (28,29), it is quite possible that combination of 
various drugs with n-3 FA may increase the death of 
inflammatory cells, thereby, further increasing the 
therapeutic benefits of the drugs (30).  N-3 FA initially 
provided beneficial effects in the control of renal disease in 
animal models and IgA nephropathy in humans (31-34). 
Our own studies, either with calorie restriction (CR) or FO, 
or recently with a combination of FO and CR, have shown 
several beneficial effects on antioxidant enzyme mRNA 
levels in B/W and MRL/lpr mice (26, 35-42).  When B/W 
mice were fed ad libitum (AL), with either 5% corn oil 
(CO) or 5% FO, a significant increase in lifespan was noted 
in FO fed mice. In contrast, when 5% CO diet fed 40% CR 
mice, they lived much longer (almost double the life-span) 
whereas, when fed a diet with 5% FO with CR they, lived 
much longer than CO + CR fed mice . Several recent 
studies have also shown numerous beneficial effects of n-3 
FA on normal strains of mice and rats as well as in healthy 
humans (43-49). The beneficial effects of n-3 FA have now 
been linked to changes in various genes and transcription 
factors including novel bioactive mediators, for example, 
resolvins, docosatrienes and protectins (11,50-53). Our 
ongoing studies on T-cell differentiation for Th1 and Th2 
cytokine inhibition by n-3 FA and down regulation of NF-
kappaB and other transcription factors (T bet) are likely to 
reveal new mechanistic information.  
 
  In the early years of research with n-3 FA, 
several adverse effects of FO were noted in humans and 
animals primarily because of oxidation of the oils. We, 
therefore, undertook detailed studies using vitamin E (vit-
E) and we and others also reported much favorable results 
particularly, elevated antioxidant enzymes in n-3 FA + CR 
fed mice which may have decreased free radicals and 
facilitated in increasing the life span (36). Soon afterwards, 
the value of antioxidants on prevention of oxidation, 
particularly during storage of the capsules was recognized. 
Currently, odor-free concentrated FO with added 
antioxidants is regularly available at health food stores. 
Very recently, FDA approved OMACOR (FO) capsules are 
now available as prescription drug to treat 
hypertriglyceridemia in patients (54). Our recent studies 
clearly show that concentrated 5/50 DHA enriched FO is 
far more effective in controlling autoimmune disease and 
increasing the life-span of B/W mice (submitted for 
publication). Further, our recent studies using low levels of 
n-3 FA (5%) and CR not only showed increased longevity 
but also prevented bone loss with age (ongoing studies). 
 
2.3. n-3 fatty acids on bone 
Nutritional or dietary supplements containing 
anti-inflammatory compounds that are found in plant food 
or marine source such as fish that is consumed everyday, 
therefore, have minimal or are free from toxic side effects. 
One such nutritional supplement that affects pro-
inflammatory cytokines and protects bone is n-3 FA. n-3 
FA from oily fish decrease cytokines like IL-1beta, IL-6 
and TNF-alpha, thereby, reducing bone resorption 
(28,36,38,55-59) (Table 1). We have shown that n-3 FA 
when fed to ovariectomized young Balb/C mice,
n-3 fatty acids on autoimmunity and osteoporosis 
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Table 1. Bone Loss and the Immune System 
• The immune system has recently 
been linked to bone loss 
• Pro-inflammatory cytokines such 
as IL-1, IL-6 TNFα, GM-CSF and 
prostaglandin E2 increase 
osteoclast proliferation 
• Estrogens and TGF-β decrease 
production of these cytokines and 





Table 2.  n-3 fatty Acids Prevents Bone Loss 
• Lack of certain fatty acids in the 
diet contributes to bone loss 
• Mammals cannot synthesize fatty 
acids with a double bond past the 
∆9 position 
• Dietary intake of EFAs determines 
membrane composition in all cells 
• Membrane EFAs determine the 
production of various cytokines by 
lymphoid cells  
 
 
downregulated the expression of RANKL and inhibits 
activation of NF-kappaB suggesting that n-3 FA can inhibit 
osteoclastogenesis (60). In the case of ovariectomized 
(OVX) mice fed casein + CO, 20% bone was lost, whereas, 
casein + FO fed OVX mice had 10% bone loss. 
Interestingly, mice fed soy protein and CO had 13% bone 
loss, whereas, soy + FO had only 3% bone loss indicating 
that soy proteins + FO had far more protection against bone 
loss (Table 2).  
The mechanism by which n-3 FA affects bone 
metabolism is probably multifaceted. In young male rats, n-
3 FA have been reported to increase alkaline phosphatase 
activity (61) and in growing rats, IGF-1 and IGFBP levels 
increased (62,63). In another study, long term feeding of n-
3 FA to MRL/lpr mice (6 weeks to 12 months of age) also 
showed that BMD increased at the end of the treatment 
period (64). n-3 FA are reported to modulate osteoblast 
functions by influencing the expression of core binding 
factor alpha 1 (cbfa1). Arachidonic acid (AA) and linoleic 
acid (LA) also increased the expression of cbfa1 (65). 
These studies suggest that n-3 FA may play a role in 
increasing bone formation.  Studies on rats (F344 x BNF1) 
when fed n-3 FA showed higher serum IGF-I, parathyroid 
hormone, vitamin D, bone specific alkaline phosphatase 
and decreased urinary calcium suggesting that n-3 FA not 
only assists in bone formation but also in calcium 
absorbtion (66). Bone loss can be attributed to increased 
bone resorption by increased expression of NF-kappaB 
activity leading to osteoclastogenesis. In vitro studies have 
showed that some n-3 FA are linked to decreased NF-
kappaB expression and modulation of RANKL signaling 
(67), whereas fatty acids from CO (LA+ Arachidonic) 
showed high NF-kappaB expression. So, n-3 FA may also 
reduce bone resorption by decreasing osteoclastogenesis.  
 
 It is well established that loss of body weight, 
seen after CR, is associated with lower bone mass. 
Similarly, male F344 rats, on 40% food restricted (FR) diet 
also showed lower BMD. This study further reported that 
with age, rats fed AL lost bone whereas rats fed FR did not 
loose bone (68). Middle aged female F344 rats on 40% FR 
diet had lower cancellous bone mineral content in the 
proximal tibia, distal femur and the fourth lumbar vertebra 
when compared to that of AL rats (69). In the tibia-fibula 
junction there was increased bone resorption in the 
endocortical surface, thereby, increasing bone marrow 
space (70). In aged female Sprague Dawley rats, fed 40% 
energy restricted diet for 9 weeks, bones showed reduced 
BMD (71). In male Wistar rats, fed 80% food for 4 weeks, 
lower bone mass and strength were reported when 
compared to their AL fed counterparts (72). In male rhesus 
monkeys on 30% FR for 6 years, there was significantly 
reduced bone mineral content (73).  The mechanism by 
which FR reduced bone mass is not yet clear, but bone 
remodeling in FR animals, especially in the cortical bone, 
seems to be envelope specific, since endocortical bone 
formation rates increased significantly but there was no 
change in the periosteal bone formation rates (70). We 
strongly feel that n-3 FA when fed either AL or moderate 
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